Masters Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Masters Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.6M	Hold	1,000,000	–	–	1.48%	18
2026 Q1	$60.6M	Buy	+1,000,000	New	+$58.3M	2%	11
2025 Q4	–	Sell	-1,000,000	Closed	-$45.1M	–	79
2025 Q3	$45.1M	Hold	1,000,000	–	–	1.63%	15
2025 Q2	$46.3M	Sell	1,000,000 -1,000,000	-50%	-$49.1M	1.8%	18
2025 Q1	$122M	Hold	2,000,000	–	–	6%	3
2024 Q4	$113M	Buy	+2,000,000	New	+$112M	4.18%	6
2020 Q3	–	Sell	-600,000	Closed	-$35.3M	–	53
2020 Q2	$35.3M	Buy	600,000 +300,000	+100%	+$17.9M	3.99%	8
2020 Q1	$16.7M	Buy	+300,000	New	+$18.3M	1.94%	11
2018 Q4	–	Sell	-1,527,000	Closed	-$94.8M	–	57
2018 Q3	$94.8M	Buy	1,527,000 +500,000	+49%	+$29.7M	2.34%	14
2018 Q2	$56.8M	Sell	1,027,000 -5,000	-0.5%	-$270K	1.6%	15
2018 Q1	$65.3M	Buy	1,032,000 +32,000	+3%	+$2.06M	1.42%	19
2017 Q4	$61.3M	Buy	1,000,000 +610,000	+156%	+$38.2M	1.47%	21
2017 Q3	$24.9M	Buy	+390,000	New	+$22.8M	0.58%	43
2014 Q1	–	Sell	-1,000,000	Closed	-$53.1M	–	56
2013 Q4	$53.1M	Buy	+1,000,000	New	+$50.9M	2.23%	11

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Masters Capital Management's BMY Position: Q1 2026 in Review

Masters Capital Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 300,000 shares — an estimated $17.5M sold.

Masters Capital Management first reported a position in BMY in Q3 2017 and held it in 6 quarters. The position peaked at $29.6M in Q3 2021. 2,537 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Masters Capital Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
Masters Capital Management sold 300,000 Bristol-Myers Squibb shares in Q1 2026, an estimated $17.5M.
Masters Capital Management first reported a position in Bristol-Myers Squibb in Q3 2017 and held it in 6 quarters.
Masters Capital Management's Bristol-Myers Squibb position peaked at $29.6M in Q3 2021.
2,537 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Masters Capital Management's 13F filing for Q1 2026, filed 15 May 2026.